Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	215.83B
Revenue (ttm)	13.05B
Net Income (ttm)	4.65B
Shares Out	5.95B
EPS (ttm)	0.78
PE Ratio	46.42
Forward PE	42.37
Dividend	0.34 (0.98%)
Ex-Dividend Date	Jul 3, 2025

Volume	14,102,507
Average Volume	9,923,238
Open	34.70
Previous Close	34.30
Day's Range	34.05 - 36.35
52-Week Range	15.96 - 37.55
Beta	0.65
RSI	71.58
Earnings Date	Aug 26, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY